# Contact This TB-500 Editorial Project | TB-500

> Contact Prescribed TB-500, an independent editorial digest of the thymosin beta-4 literature on TB-500. For corrections and source questions only — not medical, legal, or purchasing inquiries.

Corrections, source questions, and editorial feedback — the channel for keeping the record accurate.

## Reach the editors

Prescribed TB-500 is an editorial digest of the published thymosin beta-4 literature on TB-500, and this form reaches the people who maintain it. The most useful messages point to a citation that needs correcting, a study we should add, or a place where a finding's species, dose or full-length-vs-fragment status could be stated more precisely. We read every note in that spirit — the goal is a record that holds up.

Use the form below to send a message. A subject line that names the page and the specific claim helps us act on it quickly. If you are citing a study we have, quoting the reference number from the page speeds things up; if you are pointing us to one we are missing, a DOI or PubMed link is ideal.

## What we cannot answer

We cannot provide medical or legal advice, dosing guidance, or treatment recommendations, and we cannot tell you whether TB-500 is appropriate for any person or situation — those questions belong with a licensed professional. We also do not sell TB-500, do not supply it, and cannot direct you to anyone who does; we name no products, pharmacies, clinics, or vendors, and purchasing inquiries will not receive a referral. This is a research digest. Questions about the studies and the sources are exactly what this channel is for; everything beyond that sits outside what an editorial project can responsibly handle. To be concrete: we will not estimate a dose, suggest a route, comment on whether a given supplier or formulation is legitimate, or interpret the regulatory status as it applies to your circumstances. Those are not evasions — they are the boundary of what an editorial digest can responsibly do. The studies and their sources are the whole of our remit, and on those we are glad to be corrected.

---

A developer-console reading of the TB-500 record — the actin-binding fragment logged against its studies, with the full-length thymosin beta-4 caveat flagged in every diff, no clinic behind the terminal and nothing here prescribed or sold.